ES2971550T3 - Receptor de antígeno quimérico de dominio I específico para ICAM-1 - Google Patents
Receptor de antígeno quimérico de dominio I específico para ICAM-1 Download PDFInfo
- Publication number
- ES2971550T3 ES2971550T3 ES17851258T ES17851258T ES2971550T3 ES 2971550 T3 ES2971550 T3 ES 2971550T3 ES 17851258 T ES17851258 T ES 17851258T ES 17851258 T ES17851258 T ES 17851258T ES 2971550 T3 ES2971550 T3 ES 2971550T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- car
- icam
- domain
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 title claims abstract description 113
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 title claims abstract description 112
- 108010083359 Antigen Receptors Proteins 0.000 title description 2
- 102000006306 Antigen Receptors Human genes 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 152
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 128
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- 241000282414 Homo sapiens Species 0.000 claims abstract description 37
- 201000011510 cancer Diseases 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 9
- 238000011467 adoptive cell therapy Methods 0.000 claims abstract description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 93
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 51
- 230000004913 activation Effects 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 230000035772 mutation Effects 0.000 claims description 13
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 108090000586 somatostatin receptor 2 Proteins 0.000 claims description 10
- 102000004052 somatostatin receptor 2 Human genes 0.000 claims description 10
- 230000000139 costimulatory effect Effects 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 150000007523 nucleic acids Chemical class 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 5
- 102000005962 receptors Human genes 0.000 claims description 5
- 108020003175 receptors Proteins 0.000 claims description 5
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 4
- -1 ICOS-1 Proteins 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 230000003213 activating effect Effects 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100027207 CD27 antigen Human genes 0.000 claims description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 2
- 101000632994 Homo sapiens Somatostatin Proteins 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 102000045305 human SST Human genes 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 101710145634 Antigen 1 Proteins 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 35
- 230000008685 targeting Effects 0.000 abstract description 7
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 description 47
- 102000036639 antigens Human genes 0.000 description 47
- 108091007433 antigens Proteins 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 24
- 239000013598 vector Substances 0.000 description 21
- 102100025278 Coxsackievirus and adenovirus receptor Human genes 0.000 description 18
- 238000011534 incubation Methods 0.000 description 16
- 230000001988 toxicity Effects 0.000 description 16
- 231100000419 toxicity Toxicity 0.000 description 16
- 241001529936 Murinae Species 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 108010044426 integrins Proteins 0.000 description 14
- 102000006495 integrins Human genes 0.000 description 14
- 102000004127 Cytokines Human genes 0.000 description 13
- 108090000695 Cytokines Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 12
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 12
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 12
- 239000011324 bead Substances 0.000 description 12
- 239000002158 endotoxin Substances 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 229920006008 lipopolysaccharide Polymers 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 10
- 241000713666 Lentivirus Species 0.000 description 10
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 238000002600 positron emission tomography Methods 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 238000004020 luminiscence type Methods 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 102000043559 human ICAM1 Human genes 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 230000034994 death Effects 0.000 description 7
- 231100000517 death Toxicity 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000700 radioactive tracer Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 5
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 5
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 5
- 108700008625 Reporter Genes Proteins 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000004816 latex Substances 0.000 description 5
- 229920000126 latex Polymers 0.000 description 5
- 230000001177 retroviral effect Effects 0.000 description 5
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108091033409 CRISPR Proteins 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
- 230000006044 T cell activation Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000011201 multiple comparisons test Methods 0.000 description 4
- 210000004986 primary T-cell Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012114 Alexa Fluor 647 Substances 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 229930182816 L-glutamine Natural products 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000010361 transduction Methods 0.000 description 3
- 230000026683 transduction Effects 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 101100339431 Arabidopsis thaliana HMGB2 gene Proteins 0.000 description 2
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000331 Firefly luciferases Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 108700010013 HMGB1 Proteins 0.000 description 2
- 101150021904 HMGB1 gene Proteins 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 102100037907 High mobility group protein B1 Human genes 0.000 description 2
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 2
- 101000738335 Homo sapiens T-cell surface glycoprotein CD3 zeta chain Proteins 0.000 description 2
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102100037906 T-cell surface glycoprotein CD3 zeta chain Human genes 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101150063416 add gene Proteins 0.000 description 2
- 230000020411 cell activation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000008029 eradication Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 231100000057 systemic toxicity Toxicity 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 230000009258 tissue cross reactivity Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 108010087967 type I signal peptidase Proteins 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JHALWMSZGCVVEM-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CC1 JHALWMSZGCVVEM-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000001446 Anaplastic Thyroid Carcinoma Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011357 CAR T-cell therapy Methods 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 102000018386 EGF Family of Proteins Human genes 0.000 description 1
- 108010066486 EGF Family of Proteins Proteins 0.000 description 1
- 101150110503 END3 gene Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800001494 Protease 2A Proteins 0.000 description 1
- 101800001066 Protein 2A Proteins 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 description 1
- 241000249107 Teschovirus A Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000012636 positron electron tomography Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000008440 thyroid gland anaplastic carcinoma Diseases 0.000 description 1
- 208000019179 thyroid gland undifferentiated (anaplastic) carcinoma Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 238000013414 tumor xenograft model Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 108010065816 zeta chain antigen T cell receptor Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70546—Integrin superfamily
- C07K14/70553—Integrin beta2-subunit-containing molecules, e.g. CD11, CD18
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Endocrinology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662383139P | 2016-09-02 | 2016-09-02 | |
| US201662419817P | 2016-11-09 | 2016-11-09 | |
| PCT/US2017/046630 WO2018052594A1 (en) | 2016-09-02 | 2017-08-11 | I domain chimeric antigen receptor specific to icam-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2971550T3 true ES2971550T3 (es) | 2024-06-05 |
Family
ID=61281980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17851258T Active ES2971550T3 (es) | 2016-09-02 | 2017-08-11 | Receptor de antígeno quimérico de dominio I específico para ICAM-1 |
Country Status (10)
| Country | Link |
|---|---|
| US (6) | US10428136B2 (OSRAM) |
| EP (1) | EP3522718B1 (OSRAM) |
| JP (1) | JP6996772B2 (OSRAM) |
| KR (1) | KR102613109B1 (OSRAM) |
| CN (1) | CN108697096B (OSRAM) |
| AU (1) | AU2017325678B2 (OSRAM) |
| CA (1) | CA3033846C (OSRAM) |
| ES (1) | ES2971550T3 (OSRAM) |
| SG (1) | SG11201901505SA (OSRAM) |
| WO (2) | WO2018052594A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3522718B1 (en) * | 2016-09-02 | 2023-07-05 | Cornell University | I domain chimeric antigen receptor specific to icam-1 |
| CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
| CA3056261A1 (en) * | 2017-04-07 | 2018-10-11 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| US11866494B2 (en) * | 2018-08-31 | 2024-01-09 | Innovative Cellular Therapeutics Holdings, Ltd. | CAR T therapy through uses of co-stimulation |
| CN116600819A (zh) * | 2020-12-09 | 2023-08-15 | 艾弗依姆恩治疗公司 | 靶向epcam和icam-1的双嵌合抗原受体 |
| CN114907485B (zh) * | 2021-02-08 | 2024-04-26 | 浙江大学 | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 |
| JP2025531030A (ja) * | 2022-09-14 | 2025-09-19 | バイオセプター （オースト） プロプライエタリー・リミテッド | 免疫細胞のインビボ検出 |
| US12385818B2 (en) | 2023-02-14 | 2025-08-12 | Saudi Arabian Oil Company | Modeling gas desorption in a subsurface reservoir |
| EP4687959A1 (en) | 2023-03-24 | 2026-02-11 | Cornell University | Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer |
| WO2025188678A1 (en) * | 2024-03-04 | 2025-09-12 | AffyImmune Therapeutics Inc. | Icam-1 targeted car constructs and methods of treatment |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083751A (en) | 1994-11-01 | 2000-07-04 | Targeted Genetics Corporation | Chimeric receptors for the generation of selectively-activatable TH-independent cytotoxic T cells |
| US5712149A (en) | 1995-02-03 | 1998-01-27 | Cell Genesys, Inc. | Chimeric receptor molecules for delivery of co-stimulatory signals |
| US6737056B1 (en) * | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU4418900A (en) | 1999-04-16 | 2000-11-02 | Celltech Therapeutics Limited | Synthetic transmembrane components |
| EP1294391B1 (en) * | 2000-06-09 | 2012-08-15 | Bristol-Myers Squibb Company | Combination of agents for inhibiting transplant rejection |
| US7176187B2 (en) | 2001-02-15 | 2007-02-13 | Board Of Regents, The University Of Texas System | Fusion proteins based upon somatostatin receptors |
| WO2007070488A2 (en) * | 2005-12-12 | 2007-06-21 | The Cbr Institute For Biomedical Research, Inc. | Integrin alpha l i domain mutants with increased binding affinity |
| US9731023B2 (en) | 2010-09-08 | 2017-08-15 | Board Of Regents, The University Of Texas System | Somatostatin receptor-based cancer therapy |
| WO2013051718A1 (ja) * | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| WO2016152786A1 (ja) * | 2015-03-20 | 2016-09-29 | 国立大学法人三重大学 | 細胞傷害性ｔ細胞放出エキソソームによる癌間質間葉系細胞を標的とした腫瘍増殖及び転移抑制に係る治療薬 |
| EP3522718B1 (en) * | 2016-09-02 | 2023-07-05 | Cornell University | I domain chimeric antigen receptor specific to icam-1 |
-
2017
- 2017-08-11 EP EP17851258.8A patent/EP3522718B1/en active Active
- 2017-08-11 JP JP2019512782A patent/JP6996772B2/ja active Active
- 2017-08-11 US US15/675,508 patent/US10428136B2/en active Active
- 2017-08-11 WO PCT/US2017/046630 patent/WO2018052594A1/en not_active Ceased
- 2017-08-11 KR KR1020197009375A patent/KR102613109B1/ko active Active
- 2017-08-11 CA CA3033846A patent/CA3033846C/en active Active
- 2017-08-11 ES ES17851258T patent/ES2971550T3/es active Active
- 2017-08-11 US US15/675,419 patent/US10577408B2/en active Active
- 2017-08-11 CN CN201780004619.1A patent/CN108697096B/zh active Active
- 2017-08-11 WO PCT/US2017/046618 patent/WO2018044534A1/en not_active Ceased
- 2017-08-11 AU AU2017325678A patent/AU2017325678B2/en active Active
- 2017-08-11 SG SG11201901505SA patent/SG11201901505SA/en unknown
-
2019
- 2019-09-25 US US16/582,206 patent/US11046748B2/en active Active
-
2020
- 2020-02-11 US US16/787,539 patent/US11634471B2/en active Active
-
2021
- 2021-06-21 US US17/304,412 patent/US12410235B2/en active Active
-
2023
- 2023-03-21 US US18/187,268 patent/US12325736B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230265165A1 (en) | 2023-08-24 |
| AU2017325678A1 (en) | 2019-03-14 |
| US10428136B2 (en) | 2019-10-01 |
| US12410235B2 (en) | 2025-09-09 |
| US20180066035A1 (en) | 2018-03-08 |
| US20200017573A1 (en) | 2020-01-16 |
| CN108697096A (zh) | 2018-10-23 |
| US12325736B2 (en) | 2025-06-10 |
| CA3033846A1 (en) | 2018-03-22 |
| CN108697096B (zh) | 2022-05-03 |
| US11634471B2 (en) | 2023-04-25 |
| SG11201901505SA (en) | 2019-03-28 |
| AU2017325678B2 (en) | 2022-03-17 |
| US20180066037A1 (en) | 2018-03-08 |
| US20200181238A1 (en) | 2020-06-11 |
| JP2019530441A (ja) | 2019-10-24 |
| KR102613109B1 (ko) | 2023-12-13 |
| US20210309721A1 (en) | 2021-10-07 |
| US10577408B2 (en) | 2020-03-03 |
| CA3033846C (en) | 2025-03-11 |
| US11046748B2 (en) | 2021-06-29 |
| WO2018052594A1 (en) | 2018-03-22 |
| JP6996772B2 (ja) | 2022-02-21 |
| KR20190057072A (ko) | 2019-05-27 |
| WO2018044534A1 (en) | 2018-03-08 |
| EP3522718B1 (en) | 2023-07-05 |
| EP3522718A1 (en) | 2019-08-14 |
| EP3522718A4 (en) | 2020-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12410235B2 (en) | I domain chimeric antigen receptor specific to ICAM-1 | |
| CN113286879B (zh) | 用于细胞疗法之多样化抗原结合域、新颖平台及其他增强子 | |
| Majzner et al. | CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors | |
| KR102809774B1 (ko) | 합성 면역 수용체 및 이의 사용 방법 | |
| ES3014942T3 (en) | Methods and compositions for chimeric antigen receptor targeting cancer cells | |
| ES2989596T3 (es) | Receptores que proporcionan coestimulación dirigida para terapia celular adoptiva | |
| JP6884709B2 (ja) | 操作された免疫細胞の選別／枯渇のための、ｍＡｂが推進するキメラ抗原受容体系 | |
| CN109415409B (zh) | Flag标记的cd19-car-t细胞 | |
| ES2872077T3 (es) | Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer | |
| JP2019510498A (ja) | 癌を標的とするキメラ抗原受容体 | |
| US20210347870A1 (en) | Mesothelin-specific chimeric antigen receptor and t cells expressing same | |
| JP2018504104A (ja) | 非Ｔ細胞伝達ドメインを発現する阻害性キメラ抗原受容体（ｉＣＡＲまたはＮ−ＣＡＲ） | |
| CN111971053A (zh) | 靶向肿瘤微环境的嵌合抗原受体 | |
| KR20180030879A (ko) | 복막암을 치료하기 위한 조성물 및 방법 | |
| JP7271037B2 (ja) | 免疫シナプスを安定化させるキメラ抗原受容体（ｃａｒ）ｔ細胞 | |
| KR20190141651A (ko) | Hla-dr car-t 조성물 및 그를 제조하고 사용하는 방법 | |
| AU2021392655A1 (en) | Methods and materials for treating t cell cancers | |
| KR102957804B1 (ko) | Gpc3 car-t 세포 조성물 및 이의 제조 및 사용 방법 | |
| WO2026015911A1 (en) | Compositions and methods comprising epitopes and polypeptides |